Literature DB >> 7612238

T cell-independent antigens type 2.

J J Mond1, A Lees, C M Snapper.   

Abstract

In this review we have attempted to define the characteristics of TI-2 antigens that enable them to stimulate antibody production in the absence of T cell help. One of the most critical properties of this group of antigens is their ability to deliver prolonged and persistent signaling to the B cell. This by itself is not however sufficient to stimulate Ig synthesis, and they must therefore stimulate non-T cells to interact with the B cells either directly or indirectly via cytokine production. There is evidence implicating the NK cell and T cell as playing this important role in response to TI antigens. Furthermore, we discuss the importance of cytokines such as IL-3, GMCSF, and IFN-gamma, which significantly enhance antibody production by these antigens. Finally, we present evidence demonstrating that B cell activation via TI stimuli does not play merely a permissive role in allowing for cell cycle entry and enhanced responsiveness to other stimuli. Rather, the nature of the B cell activating signal is critical in determining the quantitative and qualitative profile of Ig isotype production.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7612238     DOI: 10.1146/annurev.iy.13.040195.003255

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  259 in total

1.  B- and T-cell immune responses to pneumococcal conjugate vaccines: divergence between carrier- and polysaccharide-specific immunogenicity.

Authors:  T L McCool; C V Harding; N S Greenspan; J R Schreiber
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Impaired immune responses and B-cell proliferation in mice lacking the Id3 gene.

Authors:  L Pan; S Sato; J P Frederick; X H Sun; Y Zhuang
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

3.  Activation of bovine B cells via surface immunoglobulin M cross-linking or CD40 ligation results in different B-cell phenotypes.

Authors:  K M Haas; D M Estes
Journal:  Immunology       Date:  2000-02       Impact factor: 7.397

4.  T cell-independent rescue of B lymphocytes from peripheral immune tolerance.

Authors:  V Kouskoff; G Lacaud; D Nemazee
Journal:  Science       Date:  2000-03-31       Impact factor: 47.728

5.  CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies.

Authors:  R S Chu; T McCool; N S Greenspan; J R Schreiber; C V Harding
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

Review 6.  Clinical implications of the specialised B cell response to polysaccharide encapsulated pathogens.

Authors:  C G Vinuesa; C de Lucas; M C Cook
Journal:  Postgrad Med J       Date:  2001-09       Impact factor: 2.401

7.  Short-circuiting long-lived humoral immunity by the heightened engagement of CD40.

Authors:  Loren D Erickson; Brigit G Durell; Laura A Vogel; Brian P O'Connor; Marilia Cascalho; Teruhito Yasui; Hitoshi Kikutani; Randolph J Noelle
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

8.  Contributions of conventional and heavy-chain IgG to immunity in fetal, neonatal, and adult alpacas.

Authors:  L P Daley-Bauer; S R Purdy; M C Smith; L F Gagliardo; W C Davis; J A Appleton
Journal:  Clin Vaccine Immunol       Date:  2010-10-06

9.  Carbohydrate antigen delivery by water soluble copolymers as potential anti-cancer vaccines.

Authors:  Qian Qin; Zhaojun Yin; Philip Bentley; Xuefei Huang
Journal:  Medchemcomm       Date:  2014-08-01       Impact factor: 3.597

10.  Foot-and-mouth disease virus can induce a specific and rapid CD4+ T-cell-independent neutralizing and isotype class-switched antibody response in naïve cattle.

Authors:  Nicholas Juleff; Miriam Windsor; Eric A Lefevre; Simon Gubbins; Pip Hamblin; Elizabeth Reid; Kerry McLaughlin; Peter C L Beverley; Ivan W Morrison; Bryan Charleston
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.